Mithramycin A

CAS No. 18378-89-7

Mithramycin A ( Plicamycin;PA 144;NSC 24559 )

Catalog No. M12838 CAS No. 18378-89-7

A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 385 In Stock
10MG 575 In Stock
25MG 888 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mithramycin A
  • Note
    Research use only, not for human use.
  • Brief Description
    A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.
  • Description
    A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA; binds to the minor groove of DNA at GC-rich sites, induces cancer cell apoptosis and metastasis.
  • Synonyms
    Plicamycin;PA 144;NSC 24559
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    DNA/RNA Synthesis
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    18378-89-7
  • Formula Weight
    1085.00
  • Molecular Formula
    C52H76O24
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@@H](O[C@H]4C[C@](C)(O)[C@H](O)[C@@H](C)O4)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)CC5=C1C(O)=C6C(O)=C(C)C(O[C@H]7C[C@@H](O[C@H]8C[C@@H](O)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)=CC6=C5
  • Chemical Name
    (2S,3S)-3-((1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl)-2-(((2S,4R,5R,6R)-4-(((2S,4R,5S,6R)-4-(((2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Boro A, et al. Int J Cancer. 2012 Nov 1;131(9):2153-64.
2. Lee TJ, et al. Mol Cancer Ther. 2006 Nov;5(11):2737-46.
3. Majee S, et al. Biochem Pharmacol. 1999 May 1;57(9):981-7.
molnova catalog
related products
  • CX-5461

    CX-5461 is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I.

  • T863

    T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.

  • UM-164

    UM-164 is a highly potent inhibitor ofc-Srcwith aKdof 2.7 nM. UM-164 also potently inhibitsp38αandp38β.